Quarterly report · Q2
2413.TEDINET S100S6AW
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥115.8bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥58.4bn | 2023-07-01 → 2023-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥230.8bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥112.6bn | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥55.6bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥34.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥16.6bn | 2023-07-01 → 2023-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥36.3bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥17.6bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥37.3bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥17.5bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥74.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥38.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥18.3bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥23.4bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥11.0bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥49.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥24.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥11.9bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥25.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥11.6bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥26.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥12.5bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥461.0bn | at 2023-09-30 | Cons. | Assets IFRS |
| Total assets | ¥400.6bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥377.7bn | at 2022-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥115.8bn | at 2023-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥91.1bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥345.2bn | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥309.5bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥291.3bn | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥264.0bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥331.6bn | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥302.6bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥284.5bn | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥135.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥118.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥100.2bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥104.3bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥26.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥57.1bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥25.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥28.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥21.9bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥18.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥15.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥22.8bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥14.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥34.47 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥16.19 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥72.22 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥35.44 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥17.58 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥34.45 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥16.18 | 2023-07-01 → 2023-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥72.17 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥35.42 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥17.57 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 71.9% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 75.5% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 75.3% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 107
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥1.8bn |
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-09-30 | −¥754m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥1.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-09-30 | −¥754m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | ¥125m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-09-30 | −¥42m |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥3.4bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥3.4bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥21m |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥6m |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥674m |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥6.9bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥13.6bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥215m |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥101m |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥3.6bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥45.5bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥23.6bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥44.0bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥22.9bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.5bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥622m |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥18.4bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥9.5bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥32.7bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥16.9bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥32.6bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥16.9bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥11m |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥0 |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥7.3bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥3.6bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥15.3bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥7.7bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥15.3bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥7.7bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥7m |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥4m |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥945m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥116.4bn |
| —segment total | revenue | 2023-07-01 → 2023-09-30 | ¥58.5bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥114.6bn |
| —segment total | revenue external | 2023-07-01 → 2023-09-30 | ¥57.8bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.7bn |
| —segment total | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥733m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥34.4bn |
| —segment total | segment profit | 2023-07-01 → 2023-09-30 | ¥16.5bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥2.8bn |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-09-30 | −¥1.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥2.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-09-30 | −¥1.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥701m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | −¥231m |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥8.4bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥2.9bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥445m |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥179m |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥3.5bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥634m |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥14.0bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥13.7bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥6.6bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥347m |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥185m |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥42.5bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥22.3bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥40.9bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥21.6bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.6bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥664m |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥18.8bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥10.0bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥30.2bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥15.3bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥30.2bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥15.3bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4m |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥2m |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥8.1bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥4.1bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥18.8bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥8.6bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥18.5bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥8.6bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥304m |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.3bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥865m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥113.9bn |
| —segment total | revenue | 2022-07-01 → 2022-09-30 | ¥55.9bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥111.2bn |
| —segment total | revenue external | 2022-07-01 → 2022-09-30 | ¥54.8bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| —segment total | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥1.0bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥36.9bn |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥17.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 811
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenue from external customers IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000OverseasReportableSegmentMember | 15266000000 | JPY |
| Revenue from external customers IFRS | Prior1QuarterDuration_ReportableSegmentsMember | 54842000000 | JPY |
| Revenue from external customers IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000OtherEmergingBusinessMember | 779000000 | JPY |
| Revenue from external customers IFRS | Prior1QuarterDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | Prior1QuarterDuration | 55621000000 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000MedicalPlatformReportableSegmentMember | 664000000 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000EvidenceSolutionReportableSegmentMember | 185000000 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000CareerSolutionReportableSegmentMember | 179000000 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000SiteSolutionReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000OverseasReportableSegmentMember | 2000000 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration_ReportableSegmentsMember | 1029000000 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000OtherEmergingBusinessMember | 26000000 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration_ReconcilingItemsMember | -1055000000 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration | － | JPY |
| Revenue IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000MedicalPlatformReportableSegmentMember | 22313000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000EvidenceSolutionReportableSegmentMember | 6829000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000CareerSolutionReportableSegmentMember | 2902000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000SiteSolutionReportableSegmentMember | 8559000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000OverseasReportableSegmentMember | 15268000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_ReportableSegmentsMember | 55871000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000OtherEmergingBusinessMember | 804000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_ReconcilingItemsMember | -1055000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration | 55621000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000MedicalPlatformReportableSegmentMember | 9976000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000EvidenceSolutionReportableSegmentMember | 2014000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000CareerSolutionReportableSegmentMember | 634000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000SiteSolutionReportableSegmentMember | 865000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000OverseasReportableSegmentMember | 4078000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_ReportableSegmentsMember | 17566000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000OtherEmergingBusinessMember | 263000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_ReconcilingItemsMember | -231000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration | 17599000000 | JPY |
| Finance income and expenses net IFRS | Prior1QuarterDuration | 720000000 | JPY |
| Profit loss before tax IFRS | Prior1QuarterDuration | 18319000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000MedicalPlatformReportableSegmentMember | 658000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000EvidenceSolutionReportableSegmentMember | 139000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000CareerSolutionReportableSegmentMember | 24000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000SiteSolutionReportableSegmentMember | 305000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000OverseasReportableSegmentMember | 619000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1QuarterDuration_ReportableSegmentsMember | 1745000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000OtherEmergingBusinessMember | 54000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1QuarterDuration_ReconcilingItemsMember | － | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1QuarterDuration | 1799000000 | JPY |
| Reversal of impairment losses IFRS IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000MedicalPlatformReportableSegmentMember | 820000000 | JPY |
| Reversal of impairment losses IFRS IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000EvidenceSolutionReportableSegmentMember | － | JPY |
| Reversal of impairment losses IFRS IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000CareerSolutionReportableSegmentMember | － | JPY |
| Reversal of impairment losses IFRS IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000SiteSolutionReportableSegmentMember | － | JPY |
| Reversal of impairment losses IFRS IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000OverseasReportableSegmentMember | － | JPY |
| Reversal of impairment losses IFRS IFRS | Prior1QuarterDuration_ReportableSegmentsMember | 820000000 | JPY |
| Reversal of impairment losses IFRS IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E05425-000OtherEmergingBusinessMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |